Purpose: To investigate the impact of the time interval (TI) between prostate biopsy and robotassisted radical prostatectomy (RARP) on the risk of biochemical recurrence (BCR). Methods: We retrospectively reviewed the medical records of 793 consecutive patients who were treated with RARP at our institution. Patients were divided into three groups, according to TI, to compare BCR-free survival (BCRFS) rates: Group 1 (n = 196), TI < 3 months; Group 2 (n = 513), 3 ≤ TI < 6 months; Group 3 (n = 84), TI ≥ 6 months. Eighty-three patients with TI ≥ 6 months were matched with an equal number of patients with TI < 6 months based on propensity scores by using four preoperative factors: prostate-specific antigen (PSA), primary (pGS) and secondary (sGS) Gleason score and positive prostate biopsy. Results: The 5-year BCRFS rates for TI Groups 1, 2, and 3 were 76%, 80.7% and 82.6% (P = 0.99), respectively. The multivariate analysis revealed that PSA, pGS, sGS and a positive prostate biopsy were independent preoperative risk factors for BCR. The propensity adjusted 5-year BCRFS for patients with TI ≥ 6 months was 84.0%. This was not worse than that of patients with TI < 6 months (71.0%, P = 0.18). Conclusions: In our cohorts, a delay in the time from biopsy to RARP did not significantly affect recurrence. Therefore, hasty treatment decisions are unnecessary for at least 6 months after diagnosis of early prostate cancer.
Introduction
Prostate cancer (PCa) is one of the leading malignancies in men worldwide; in Japan, its frequency ultimately reached an all-time high in 2015 (1) . In 2015, PCa was diagnosed in 98 400 individuals in Japan, and it accounted for 17.6% of all malignancies in Japanese men (1) . Prostate-specific antigen (PSA) screening has resulted in an increase in the number of PCa cases detected at an earlier stage. Therefore, the number of PCa patients with organconfined disease is also increasing. This trend has resulted in longer wait times for surgery, especially in high-volume centers. The adverse effect of the time interval (TI) between diagnosis and curative therapy on oncological and survival outcomes has been reported for bladder (2) , lung (3, 4) , rectal (3), breast (5, 6 ) and head and neck cancers (7) . However, several studies have found that the TI between prostate biopsy and radical prostatectomy does not adversely affect biochemical recurrence (BCR) and pathological outcomes (8) (9) (10) (11) (12) (13) (14) , even in high-risk patients (8, (10) (11) (12) 14) . This is because PCa is a more slow-growing, indolent cancer than the other cancer types mentioned above. However, other studies have reported that a prolonged TI has a negative impact on BCR and pathological outcome (15) (16) (17) (18) . Nam et al. and O'Brien et al. reported that a surgical delay ≥6 months was associated with worse BCR, even in D'Amico low-risk men (18, 19) . Nguyen demonstrated that TI > 2.5 months resulted in higher BCR rates in D'Amico highrisk patients who underwent external beam radiation therapy (17) . Therefore, the effect of TI is controversial. One reason for this controversy is that, to date, there has been no randomized prospective study that analyzed TI and oncological outcomes. It is possible that clinicians empirically decide on curative treatments earlier for patients who are expected to have a worse prognosis, resulting in a so-called treatment selection bias.
Propensity score matching analysis can reduce treatment selection bias between patient groups by adjusting for the multiple preoperative confounding variables that can affect oncological outcomes. We performed propensity score matching analysis to investigate the potential impact of treatment delays in patients with localized PCa.
Materials and methods
After receiving institutional review board approval, we retrospectively reviewed the medical records of 1458 patients who had been treated with robot-assisted radical prostatectomy (RARP) for T1-3N0M0 PCa at Tokyo Medical University Hospital between October 2006 and July 2015. Patients who underwent neoadjuvant hormone treatment or radiation therapy were excluded (n = 300). Patients who met the following exclusion criteria were also excluded: unknown date for their transrectal ultrasound-guided biopsy (n = 16); insufficient clinical and pathological data available (n = 64); or lost to follow-up, or postoperative follow-up period <6 months (n = 266); patients with TI longer than 12 months because of active surveillance (n = 19). Finally, a total of 793 patients were enrolled in this study. TI was calculated as the time from the date of the prostate biopsy to the date of RARP. The 793 patients were divided into three groups according to TI: Group 1 (n = 196), TI < 3 months; Group 2 (n = 513), 3 ≤ TI < 6 months; Group 3 (n = 84), TI ≥ 6 months. Clinicopathological outcomes and biochemical recurrence-free survival rates (BCRFS) after RARP were compared between the three groups. A multivariate Cox analysis was used to identify the independent significant preoperative risk factors for BCR. Using these independent preoperative risk factors, a propensity score matching analysis was conducted to adjust for the preoperative characteristics between two patient groups: Group A, TI < 6 months; Group B, TI ≥ 6 months. Clinicopathological outcomes and BCRFS between the two groups were compared to investigate the impact of TI ≥ 6 months on oncological outcomes after RARP.
Clinical stage was defined according to the 2002 TNM staging system. Pathological outcomes such as pathological stage and Gleason score in RARP specimens were obtained from the official pathology reports. Gleason upgrading was defined as an increase from the biopsy Gleason score. The increases were grouped as follows: 5-6, 3 + 4, 4 + 3, 8, 9 and 10. BCR was defined as two consecutive PSA measurements of ≥0.2 ng/ml. The day of surgery was considered the day of BCR if postoperative serum PSA levels were >0.2 ng/ml.
Surgical procedure and technique
Our surgical techniques for treating localized PCa using RARP have been previously described in detail (20) . In brief, the procedures were performed using a six-port technique via the transperitoneal space in the usual fashion, based on a previously established method described by Patel et al. (21) .
Analysis
Comparisons between the three groups were performed using the analysis of variance (ANOVA) test for continuous variables and the chi-square test for categorical variables. The Bonferroni correction was used for each pairwise comparison. The Kaplan-Meier method and the log-rank test were used to obtain and compare BCRFS between the three patient groups. Multivariate analysis was used to identify independent prognostic variables affecting BCR after RARP using a stepwise Cox proportional hazards regression model.
Propensity score matching was defined by Rosenbaum and Rubin (1983) as a method to reduce the bias in the estimation of treatment effects (22) (23) (24) . Propensity scoring has become a popular approach in medical trials to estimate causal treatment effects by minimizing treatment selection bias. All of the statistical analyses were performed using R for Windows, version 3.1.0 (R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project. org/). For all statistical comparisons, differences with a P < 0.05 were considered significant.
Results
The median follow-up period after RARP in the present study was 32.3 months (interquartile range [IQR], 6.1-102.3 months). Overall, the median TI from prostate biopsy to RARP was 3.8 months (IQR, 1.1-11.4 months). There were 196 patients in Group 1 with TI < 3 months, 513 patients in Group 2 with 3 ≤ TI < 6 months, and 84 patients in Group 3 with TI ≥ 6 months ( Table 1) . As shown in Table 1 , patients in Group 1 had a higher primary Gleason score (pGS) than patients in Group 2 (P = 0.0065). Both the number of positive prostate biopsy cores and the percentage of positive prostate biopsy cores significantly decreased with increasing TI (P = 0.00034 and P = 0.0020, respectively) ( Table 1) . Pathological outcomes after RARP are shown in Table 2 . The rates of pathological pT3-4 and seminal invasion were significantly higher in Group 1 than in Group 2 (P = 0.020 and P = 0.0040, respectively). The rate of upstaging after RARP was significantly higher in Group 1 than in Group 2 (27.6% vs. 18.7%, P = 0.039), while the rate of Gleason upgrading was not significant between the three groups (P = 0.53).
The 5-year BCRFS rates in Group 1, 2, and 3 were 76%, 80.7% and 82.6%, respectively. These were not significant differences according to the log-rank test (P = 0.99) (Fig. 1A) .
Patients were classified as low-, intermediate-or high-risk according to the D'Amico risk criteria. For Group 1 patients, the distribution of low-, intermediate-and high-risk classifications was 32.1%, 51.5% and 16.3%, respectively; for Group 2 patients, the distribution was 28.1%, 52.8% and 19.1%, respectively; and for Group 3 patients, the distribution was 25%, 53.6%, and 21.4%, respectively (P = 0.50) ( Table 1) . Regarding BCRFS, for the lowrisk patients in Groups 1, 2 and 3, the 5-year BCRFS rates were 96.9%, 85.6% and 94.4%, respectively (P = 0.36); for the intermediate-risk patients, these rates were 83.1%, 84.9% and 78.0%, respectively (P = 0.32); and for the high-risk patients, these rates were 53.6%, 68.8% and 82.5%, respectively (P = 0.41) (Fig. 1B) .
On multivariate analysis using a stepwise Cox proportional hazards regression model, PSA (Hazard Ratio [HR] = 1.05, P < 0.001), pGS (pGS 4, HR = 2.9, P < 0.001; pGS 5, HR = 5.4, P < 0.001), secondary Gleason score (sGS) (sGS 5, HR = 1.8, P = 0.026), and the number of positive prostate biopsy cores (HR = 1.1, P = 0.017) were statistically significant independent preoperative risk factors for BCR in our cohort (Table 3) .
Taking these results, the propensity score matching to minimize treatment selection biases was based on four preoperative factors: preoperative serum PSA level, pGS and sGS of the prostate biopsy, and number of positive prostate biopsy cores. As a result, 83/84 patients with TI > 6 months (Group B) were matched 1:1 with equal number of patients with TI < 6 months (Group A). Patient characteristics and clinicopathological outcomes are shown in Table 4 . The propensity adjusted 5-year BCRFS in Group A was 71.0%; this was not significantly better than the rate of 84.0% obtained in Group B (log-rank test, P = 0.18) (Fig. 2) . Similarly, for D'Amico high-risk patients, the propensity adjusted 5-year BCRFS rates for Group A and Group B were 72.4% and 88.2%, respectively (log-rank test, P = 0.17). There were no significant differences with regards to Gleason upgrading (P = 0.51) or upstaging (P = 1.0) after propensity adjustments between the two groups ( Table 4) .
Discussion
This is the first study using a propensity score matching analysis to evaluate the impact of TI between prostate biopsy and RARP in the robotic prostatectomy era. PCa is generally considered a relatively slow-glowing malignancy, and screening adds a considerable lead time. Therefore, a delay from diagnosis to active therapy, such as radical prostatectomy or radiation therapy, is common in the clinical setting. There has been much discussion in the literature regarding the significance of TI between prostate biopsy and curative treatment and this was summarized in a recent review article (25) . Dall'Era et al. and van den Bergh et al. reported that a delay in treatment had no significant impact on oncological outcomes, with the exception of patients with a D'Amico low-risk classification (9, 13) . Five studies reported that a delay in treatment had no significant impact on oncological outcomes, even in patients with intermediate-and high-risk D'Amico classifications (8, (10) (11) (12) 14) . The results of the present study appear to be in line with those of these previous studies. Unfortunately, the quality of the evidence in the previous studies was low because of the retrospective designs and lack of randomization (evidence level ≤3) (25) . Additionally, most studies showed evidence of a selection bias in which patients with more unfavorable risks were treated earlier. When we debate this kind of issue, it is important to adjust for this treatment selection bias that is unconsciously induced by the clinician. In fact, in our cohort, patients who were treated immediately (<3 months) after prostate biopsy had worse pathological features in their biopsy specimens (Table 1 ) and more extraprostatic disease in radical prostatectomy specimens (Table 2) , whereas standard comparison factors such as PSA, biopsy Gleason score, clinical T stage and distribution of D'Amico risk classification were not significantly different. When making treatment decisions, most urologists consider not only the standard factors, but also other established preoperative prognostic factors including the detailed analysis of biopsy specimens and age. Thus, we tried to perform a more precise comparative analysis using propensity score matching; this is an alternative method for estimating the effect of treatment when random assignment of treatments is not feasible. Surprisingly, there were no significant differences in either BCR or pathological upgrading or upstaging after propensity-matching adjustments between patients with TI < 6 months and those with TI ≥ 6 months ( Fig. 2 and Table 4 ). Such findings may be explained by the relatively slow progression of PCa. For example, a study by Epstein et al. demonstrated little evidence of worsening tumor grade in the short term (<18 months) after biopsy (26) . Our results could mean that hasty treatment decisions are unnecessary for at least 6 months after a diagnosis. These results are important for preoperative clinical counseling for both urologists and patients, especially at high-volume hospitals because patients often feel uneasy when their surgery is scheduled for a date far into the future.
There are some limitations in the present study. First, this study had a retrospective design, although we excluded treatment selection bias and adjusted patient characteristics by using a propensity score matching analysis. A randomized study needs to reach a definitive answer, but it is impossible to ask a patient to wait longer for treatment. Therefore, a matching-retrospective study or meta-analysis may be a more realistic option. Second, the number of patients enrolled after propensity score matching was somewhat small, resulting in weak statistical power. Studies of larger patient cohorts are recommended to confirm the impact. Finally, our results and conclusions are limited to patients with early phase cancer who are good candidates for local therapy such as surgery and radiation. Our results may not be the same for patients with very high-risk/locally advanced cancer.
Conclusion
A delay in surgical treatment of at least 6 months from biopsy to RARP did not have a significant impact on outcome, even in D'Amico high-risk patients with PCa. Therefore, hasty treatment decisions are unnecessary for at least 6 months after diagnosis of early PCa. However, we suppose that our results may not be same for patients with very high-risk/locally advanced cancer.
